Product guide · Food supplement
Genetic Nutrition Laboratories Triglyceride Omega 3 Sport Edition
Omega-3 fish oil softgels from GN Laboratories. This guide sets out what the manufacturer states about the composition of Genetic Nutrition Laboratories Triglyceride Omega 3 Sport Edition, what independent research says about its main ingredients, and the safety and regulatory points that apply.
Back to the product- Named ingredients
- 3
- Amounts stated
- All
- Status
- Food supplement
- Evidence summaries
- 1
Overview
Manufacturer informationTriglyceride Omega 3 provides 500 mg EPA and 250 mg DHA in every 1000 mg of fish oil, in the natural triglyceride form, in softgel capsules.
Ingredients & composition
Manufacturer information| Ingredient | Amount |
|---|---|
| Fish oil | 1000 mg |
| EPA | 500 mg |
| DHA | 250 mg |
Scientific background
Independent researchOmega-3 fatty acids (EPA and DHA)
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain omega-3 fatty acids found mainly in oily fish. DHA is a structural component of the brain and the retina3.
EFSA set an adequate intake of 250 mg of EPA plus DHA a day for adults3. Fish oil supplements supply them as natural triglycerides, re-esterified triglycerides or ethyl esters; bioavailability differs between these forms4.
Research evidence
Independent researchOmega-3 fatty acids (EPA and DHA)
The EU authorises health claims that EPA and DHA contribute to the normal function of the heart (from 250 mg EPA + DHA a day), and that DHA contributes to normal brain function and normal vision (from 250 mg DHA a day)5.
For preventing cardiovascular disease, the evidence is mixed. A Cochrane review found little or no effect of increasing long-chain omega-3 intake on overall death and cardiovascular events, while moderate- and low-certainty evidence suggested small reductions in coronary heart disease deaths and events, and lower blood triglycerides6. In the VITAL trial, 1 g a day of marine omega-3 did not lower the rate of major cardiovascular events or cancer compared with placebo7.
A large trial of 4 g a day of icosapent ethyl, a prescription purified EPA medicine, reduced cardiovascular events in people with raised triglycerides on statins8. That result applies to the medicine at that dose, not to ordinary fish oil supplements.
Evidence limitations
Independent researchNo published study has tested this specific product; the research summarised here concerns the ingredient itself.
Safety & potential risks
For this product
At the manufacturer's suggested 1–2 softgels a day, intake would be about 750–1500 mg EPA plus DHA. This is well below the 5 g a day that EFSA considers safe for adults1, but intakes above 1 g a day were associated with a higher risk of atrial fibrillation in cardiovascular outcome trials2.
- Do not exceed the recommended daily dose.
- Food supplements should not be used as a substitute for a varied and balanced diet and a healthy lifestyle.
- Keep out of the reach of young children.
Omega-3 fatty acids (EPA and DHA)
EFSA concluded that supplemental intakes of EPA and DHA combined of up to 5 g a day do not raise safety concerns for adults1.
A meta-analysis of cardiovascular outcome trials found a higher risk of atrial fibrillation with long-term marine omega-3 supplementation, mainly at doses above 1 g a day2. People taking blood-thinning medication, or with heart-rhythm problems, should speak to a doctor first.
Fish oil is a fish product and can cause reactions in people with fish allergy.
Regulatory status
Sold as a food supplement. Health claims shown are authorised EU claims (Regulation 432/2012) and apply at the stated daily amount.
Scientific references
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Journal. 2012;10(7):2815. DOI 10.2903/j.efsa.2012.2815
- Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144:1981-1990. PubMed 34612056
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on Dietary Reference Values for fats. EFSA Journal. 2010;8(3):1461. DOI 10.2903/j.efsa.2010.1461
- Dyerberg J, Madsen P, Møller JM, et al. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010;83:137-141. PubMed 20638827
- Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods. Official Journal of the European Union. Source
- Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3:CD003177. PubMed 32114706
- Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23-32. PubMed 30415637
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22. PubMed 30415628
- Directive 2002/46/EC on the approximation of the laws of the Member States relating to food supplements. Official Journal of the European Union. Source
Sources checked against PubMed, Crossref or the official publisher on 2026-11-04. Manufacturer information is taken from the product's own data and has not been independently tested.
The product
Genetic Nutrition Laboratories Triglyceride Omega 3 Sport Edition
€35,90